Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: Biochemical and pathological evidences for beneficial effect of pioglitazone

Human and Experimental Toxicology

Volumn 31, Issue 9, 2012, Pages 887-897

  Rezvanfar, M A ^a,a,b   Ahmadi, A ^c   Saadi, Ha Shojaei ^d   Baeeri, M ^a   Abdollahi, M ^a,b,e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c URMIA UNIVERSITY   (Iran)

^d UNIVERSITY OF CALGARY   (Canada)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

hyperandrogenism; inflammatory mediators; letrozole; oxidative stress; pioglitazone; polycystic ovary

Indexed keywords

BIOLOGICAL MARKER; CATALASE; ESTRADIOL; GLUTATHIONE PEROXIDASE; LETROZOLE; PEROXYNITRITE; PIOGLITAZONE; PROGESTERONE; PROSTAGLANDIN E; SUPEROXIDE DISMUTASE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; ESTRADIOL BLOOD LEVEL; ESTRUS CYCLE; FEMALE; GRANULOSA CELL; INCIDENCE; INFLAMMATION; LIPID PEROXIDATION; NITROSATIVE STRESS; NONHUMAN; OVARY CYST; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RAT; TESTOSTERONE BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AROMATASE INHIBITORS; ESTRADIOL; FEMALE; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; NITRILES; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; PPAR GAMMA; PROGESTERONE; PROSTAGLANDINS E; RATS; RATS, WISTAR; TESTOSTERONE; THIAZOLIDINEDIONES; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE; RATTUS;

EID: 84863463566     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327111426589     Document Type: Article

References (72)

1. Chen ZG, Luo LL, Xu JJ, Zhuang XL, Kong XX, Fu YC. Effects of plant polyphenols on ovarian follicular reserve in aging rats. Biochem Cell Biol. 2010 ; 88: 737-745
2. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003 ; 24: 633-667
3. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis on the efficacy and safety of combined vitamin C and E supplementation in preeclamptic women. Hypertens Pregnancy. 2009 ; 28: 417-434
4. Lee JY, Baw CK, Gupta S, Aziz N, Agarwal A. Role of oxidative stress in polycystic ovary syndrome. Curr Wom Health Rev. 2010 ; 6: 96-107
5. Kajbaf F, Mojtahedzadeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy. 2007 ; 4: 97-106
6. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 ; 16: 347-363
7. Cardozo E, Pavone ME, Hirshfeld-Cytron JE. Metabolic syndrome and oocyte quality. Trends Endocrinol Metab. 2011 ; 22: 103-109
8. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005 ; 28: 3
9. Agarwal A, Saleh RA, Bedaiwy MA. Role of reactive oxygen species in the pathophysiology of human reproduction. Fertil Steril. 2003 ; 79: 829-843
10. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008 ; 10: 1375-1403
11. Ruder EH, Hartman TJ, Blumberg J, Goldman MB. Oxidative stress and antioxidants: exposure and impact on female fertility. Hum Reprod Update. 2008 ; 14: 345-357
12. Ruder EH, Hartman TJ, Goldman MB. Impact of oxidative stress on female fertility. Curr Opin Obstet Gynecol. 2009 ; 21: 19-22
13. Vakilian K, Ranjbar A, Zarganjfard A, Mortazavi M, Vosough-Ghanbari S, Mashaiee S, et al. On the relation of oxidative stress in delivery mode in pregnant women; a toxicological concern. Toxicol Mech Methods. 2009 ; 19: 94-99
14. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008 ; 65: 233-239
15. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003 ; 80 (1). 123-127
16. Polak G, Kozio-Montewka M, Gogacz M, Baszkowska I, Kotarski J. Total antioxidant status of peritoneal fluid in infertile women. Eur J Obstet Gynecol Reprod Biol. 2001 ; 94 (2). 261-263
17. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest. 2001 ; 107 (2). 181-189
18. González F, Minium J, Rote NS, Kirwan JP. Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 ; 90 (9). 5336-5342
19. Hernández-Valencia M, Hernández-Rosas M, Zárate A. Care of insulin resistance in polycystic ovary syndrome. Ginecol Obstet Mex. 2010 ; 78 (11). 612-616
20. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol. 2010 ; 22 (6). 466-476
21. Glintborg D, Andersen M. Thiazolinedione treatment in PCOS -an update. Gynecol Endocrinol. 2010 ; 26 (11). 791-803
22. Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf. 2010 ; 9 (2). 347-354
23. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 ; 89 (8). 3835-3840
24. Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril. 2010 ; 94 (1). 236-241
25. Ota H, Goto T, Yoshioka T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008 ; 90 (3). 709-713
26. Rezvanfar MA, Rezvanfar MA, Ranjbar A, Baeeri M, Mohammadirad A, Abdollahi M. Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria. Pestic Biochem Physiol. 2010 ; 98: 135-143
27. Hosseini-Tabatabaei A, Esmaily H, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, et al. Benefit of nicorandil using an immunologic murine model of experimental colitis. Cent Eur J Biol. 2009 ; 4: 74-85
28. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol. 2004 ; 64: 59-74
29. Belgorosky D, Sander VA, Yorio MP, Faletti AG, Motta AB. Hyperandrogenism alters intraovarian parameters during early folliculogenesis in mice. Reprod Biomed Online. 2010 ; 20: 797-807
30. Sander VA, Piehl L, Facorro GB, Rubin de Celis E, Motta AB. Regulation of functional and regressing stages of corpus luteum development in mice. Role of reactive oxygen species. Reprod Fertil Dev. 2008 ; 20: 760-769
31. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004 ; 10: 107-117
32. Appasamy M, Jauniaux E, Serhal P, Al-Qahtani A, Groome NP, Muttukrishna S. Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation. Fertil Steril. 2008 ; 89: 912-921
33. Van Voorhis B, Dunn M, Snyder G, Weiner C. Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology. 1994 ; 135: 1799-1806
34. Seino T, Saito H, Kaneko T, Takahashi T, Kawachiya S, Kurachi H. Eight-hydroxy-2'-deoxyguanosine in granulosa cells is correlated with the quality of oocytes and embryos in an in vitro fertilization-embryo transfer program. Fertil Steril. 2002 ; 77: 1184-1190
35. Meenakumari KJ, Agarwal S, Krishna A, Pandey LK. Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz J Med Biol Res. 2004 ; 37: 1637-1644
36. Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002 ; 77 (20). 17830-17835
37. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009 ; 94 (2). 469-476
38. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003 ; 24 (5). 633-667
39. Zhou R, Bruns CM, Bird IM, Kemnitz JW, Goodfriend TL, Dumesic DA, et al. Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys. Reprod Toxicol. 2007 ; 23 (3). 438-448
40. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function - implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol. 2005 ; 3: 41
41. Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod. 2002 ; 66 (1). 190-198
42. Huang Z, Zhou X, Nicholson AC, Gotto AM, Hajjar DP, Han J. Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor. Br J Pharmacol. 2008 ; 155 (4). 596-605
43. Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004 ; 35: 103-108
44. Baravalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res. 2006 ; 37: 830-839
45. Joseph-Horne R, Mason H, Batty S, White D, Hillier S, Urquhart M, et al. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod. 2002 ; 17 (6). 1459-1463
46. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther. 2004 ; 6 (6). 850-863
47. Dorafshar AH, Moodley K, Khoe M, Lyon C, Bryer-Ash M. Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. Diab Vasc Dis Res. 2010 ; 7 (1). 20-27
48. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol. 2002 ; 448 (2-3). 231-238
49. Gumieniczek A, Krzywdziska M, Nowak M. Modulation of nitrosative/ oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide. Exp Lung Res. 2009 ; 35 (5). 371-379
50. Somi MH, Hajipour B, Asl NA, Estakhri R, Azar AN, Zade MN, et al. Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. Transplant Proc. 2009 ; 41 (10). 4105-4109
51. Medhi B, Aggarwal R, Chakrabarti A. Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. Indian J Exp Biol. 2010 ; 48 (8). 793-799
52. Rabbani SI, Kshama D, Salma Kh. Inhibitory effect of pioglitazone on type-2 diabetes induced nuclear damage in wistar rats. IJPBS. 2010 ; 1 (2). 1-10
53. Matsumoto T, Noguchi E, Kobayashi T, Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med. 2007 ; 42 (7). 993-1007
54. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005 ; 288 (4). 899-905
55. Yoo HY, Chang MS, Rho HM. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene. 1999 ; 234 (1). 87-91
56. Okuno Y, Matsuda M, Miyata Y, Fukuhara A, Komuro R, Shimabukuro M, et al. Human catalase gene is regulated by peroxisome proliferator activated receptor-gamma through a response element distinct from that of mouse. Endocr J. 2010 ; 57 (4). 303-309
57. Sundararajan S, Landreth GE. Antiinflammatory properties of PPAR gamma agonists following ischemia. Drug News Perspect. 2004 ; 17: 229-236
58. Peral B, San Millán JL, Castello R, Moghetti P, Escobar-Morreale HF. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab. 2002 ; 87 (8). 3977-3983
59. Sayin NC, Gücer F, Balkanli-Kaplan P, Yüce MA, Ciftci S, Kücük M, Yardim T. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med. 2003 ; 48 (3). 165-170
60. Amini-Shirazi N, Hoseini A, Ranjbar A, Mohammadirad A, Khoshakhlagh P, Yasa N, Abdollahi M. Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol Mech Methods. 2009 ; 19: 183-189
61. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod. 1999 ; 61 (4). 993-998
62. Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res. 2011 ; 34 (1). 20-33
63. Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther. 2010 ; 35 (5). 565-579
64. Lee TI, Kao YH, Chen YC, Chen YJ. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur J Clin Invest. 2009 ; 39 (1). 23-30
65. Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, et al. Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol. 2009 ; 147: 7
66. Navarra P, Andreani CL, Lazzarin N, Pierro E, Mirtella A, Lanzone A, et al. Increased production and release of prostaglandin-E2 by human granulosa cells from polycystic ovaries. Prostaglandins. 1996 ; 52: 187-197
67. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol. 2006 ; 530 (1-2). 70-80
68. Fahmi H, Pelletier JP, Martel-Pelletier J. PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. J Rheumatol. 2002 ; 29 (1). 3-14
69. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides and oxidative stress: a review. Med Sci Monit. 2004 ; 10 (6). RA141 - RA147
70. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005 ; 59 (7). 365-373
71. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci. 2007 ; 52 (9). 2015-2021
72. Mannerås L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007 ; 148 (8). 3781-3791